Celltrion CEO aims to sell Truxima in US this year - (The Investor via NewsPoints Desk)

  • Celltrion chairman Seo Jung-jin announced plans to introduce Truxima, a biosimilar of Roche's Rituxan, in the second half of this year, The Korea Herald reported Tuesday.

  • "Since Celltrion is directly shaping the sales strategy for the US market, instead of through our onsite partner, we will make sure to focus on gaining market share," Seo remarked.

  • Truxima was authorised by the FDA last November.

  • Seo added that Celltrion aims to launch Herzuma, a biosimilar of Roche's Herceptin, in the US early next year.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles